Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.
CONCLUSIONS: Data derived from two small RCTs indicate that STP is significantly better than placebo with regards to 50% or greater reduction in seizure frequency and seizure freedom. Adverse effects occurred more frequently with STP. Additional adequately powered studies with long-term follow-up should be conducted to unequivocally establish the long-term efficacy and tolerability of STP in the treatment of patients with SMEI.
PMID: 28521067 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Brigo F, Igwe SC, Bragazzi NL Tags: Cochrane Database Syst Rev Source Type: research
More News: Children | Clinical Trials | Conferences | Databases & Libraries | Epilepsy | General Medicine | International Medicine & Public Health | Nutrition | Study | WHO